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The neurobehavioral profile of anti-epileptic drugs (AEDs) has been a recurrent research
topic in the scientific literature. As pharmacological treatments for epilepsy continue to
evolve, there is a general consensus that newer AEDs have less detrimental side effects in
comparison to their older counterparts. Among newer AEDs and epilepsy patients, potential
risk for neurobehavioral changes has been reported with levetiracetam (LEV). Conversely,
limited data exists regarding the manifestation of this symptomatology in a subgroup of
epilepsy patients with brain tumors.The current paper reviews the literature regarding the
neurobehavioral profile of LEV in brain tumor related epilepsy and suggestions for future
research will be discussed.
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INTRODUCTION
The neurobehavioral profile of anti-epileptic drugs (AEDs) has
been a recurrent research topic in the scientific literature. As
pharmacological treatments for epilepsy evolve, there is a gen-
eral consensus that newer AEDs have less cognitive side effects
in comparison to their older counterparts. Levetiracetam (LEV)
has garnered interest as a treatment for patients with brain tumor
related epilepsy. Among patients with epilepsy, potential risk for
neurobehavioral changes has been reported with LEV. Conversely,
limited data exists regarding the manifestation of this symptoma-
tology in epilepsy patients with brain tumors. The current paper
reviews the literature regarding the neurobehavioral profile of LEV
in brain tumor related epilepsy and suggestions for future research
will be discussed.
ANTI-EPILEPTIC DRUGS
The adverse effects of AEDs have been fairly well documented
in the scientific literature and can encompass both physical and
neurobehavioral phenomena that can vary in their intensity and
their impact on patients’ quality of life (1). A meta-analysis con-
ducted by Zaccara et al. (2) revealed somnolence, dizziness, ataxia,
diplopia, and fatigue to be the most common adverse physical
symptoms of AEDs. Studies have shown that AEDs can nega-
tively impact multiple cognitive domains (3). Further, depending
on the choice of medication, AEDs may positively or negatively
affect mood. Adverse psychiatric effects often include behavioral
changes, depression, and psychosis (4). A benefit of the newer gen-
eration AEDs, such LEV, is that they tend to have less severe side
effects and a decreased potential to negatively interact with other
medications (5). As a result, there is a proclivity to consider newer
generation AEDs as the first line of treatment for diverse epileptic
syndromes, including brain tumor related epilepsy.
BRAIN TUMOR RELATED EPILEPSY
Seizures are often the initial presenting symptom of intracranial
tumors (6, 7). In a meta-analysis of prospective randomized clin-
ical trials involving newly diagnosed brain tumors, Glantz et al.
(8) found a 26% incidence of seizures occurring prior to diagnosis
and the rates can be even higher depending upon tumor grade (9,
10). The incidence of brain tumor related epilepsy varies based
on the type of tumor involved and there is an inverse correlation
between tumor grade and likelihood of seizures (7, 11). The mech-
anisms behind brain tumor related epilepsy are somewhat unclear,
although there are a number of proposed etiologic mechanisms
including tumor location, histopathological features, the neuro-
chemical profile of the tumor, and changes in neurotransmitter
and receptor expression, among others (12).
Brain tumor related epilepsy is characterized by its intractability
to anti-epileptic drugs and prior findings suggest that prophylac-
tic AED use is not effective (10). The AAN Quality Standards
Subcommittee meta-analysis regarding prophylactic use of AEDs
determined that it does not provide substantial benefit and adverse
effects are common (8). Another concern with use of AEDs in
brain tumor related epilepsy is drug–drug interactions between
AEDs and chemotherapeutic agents. Many older AEDs (e.g.,
phenobarbital, phenytoin, carbamazepine) are hepatic enzyme
inducers, which is problematic because several chemotherapeu-
tic agents are metabolized by hepatic chromosome P450 enzymes.
AEDs that induce hepatic enzymes increase the metabolism of
the chemotherapeutic agent, requiring the chemotherapy dose to
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be increased in order to maintain required blood levels (11, 13).
Enzyme inducing agents can also interact with steroids that are
commonly used to treat edema in patients with brain tumors (14).
As a result of these drug interactions, newer generation AEDs that
do not have hepatic enzyme inducing properties, such as LEV, have
been identified as a pharmacological alternative for treating brain
tumor related epilepsy (15).
LEVETIRACETAM
Levetiracetam’s mechanism of action is unclear, though some
research has supported the idea that it is involved in the expression
of synaptic vesicle protein 2A (SV2A) (12) and animal models have
shown that SV2A is the binding site for LEV (16). Patsalos (17)
noted that the pharmacokinetic profile of LEV meets nearly all the
criteria that make an AED “ideal” because of its rapid absorption,
limited metabolism, and low risk of drug interactions. It does not
inhibit or induce hepatic enzymes like many of the older genera-
tion AEDs, which decreases the likelihood of interaction with other
drugs. LEV has not been found to induce or inhibit metabolism in
other AEDs or non-AEDs, such as chemotherapeutic agents (18).
Bobustuc et al. (19) found that LEV sensitized glioblastoma to the
chemotherapeutic agent temozolomide in a sample of four newly
diagnosed patients, which provides evidence for additional prop-
erties of LEV that make it a good alternative for use in brain tumor
related epilepsy.
In terms of efficacy, multiple studies have found LEV to reduce
seizure frequency by 50% or more in the majority of brain tumor
patients when used as monotherapy and/or as adjunctive treat-
ment (6, 20–22). One study compared a group of 105 patients
receiving LEV monotherapy with 210 patients receiving pheny-
toin monotherapy and found both drugs to be effective for early
and late post-operative seizures (23). Lim et al. (24) looked at the
safety and efficacy of switching patients from phenytoin to LEV
following craniotomy in a sample of 29 patients and the two drugs
had similar numbers of seizure free patients at 6 months. In addi-
tion to its efficacy regarding seizure control, other factors, such as
its neurobehavioral profile, need to be considered.
NEUROBEHAVIORAL PROFILE OF LEVETIRACETAM
The literature regarding LEV’s neurobehavioral profile in epilepsy
has been extensively reviewed (3, 17, 25, 26) and is particularly
notable for behavioral changes (27) and increased aggression (28,
29). In particular, patients with premorbid depression or behav-
ioral problems are at greater risk for developing increased aggres-
sion (4, 29). In addition, suicidality in some patients prescribed
LEV has been reported (30).
Levetiracetam is not generally associated with cognitive side
effects (3, 25). Some of the research on LEV and brain tumor
related epilepsy has focused primarily on its efficacy related to
seizure control and limited information regarding other adverse
side effects is reported (22, 31). For the current paper, 14 stud-
ies were reviewed that reported on specific physical, behavioral,
and cognitive side effects among patients with brain tumor related
epilepsy treated with LEV.
Lynam et al. (6) conducted a retrospective analysis of 147
patients with newly diagnosed primary and metastatic brain
tumors. Forty one of the patients were on LEV and the most
commonly reported side effects included depression, fatigue, and
irritability. A limited number of cases had side effects severe
enough to discontinue the medication, though the exact num-
ber of cases went unreported (6). Newton et al. (32) conducted a
retrospective chart review of 41 patients with brain tumors (34 pri-
mary brain tumors, 6 metastatic brain tumors) who received LEV
as an add on or monotherapy and were followed for 4 weeks. In
terms of side effects, 58.5% of the sample experiences side effects,
and those on 2,000 mg or more were more likely to experience side
effects. Somnolence was the most frequently reported side effect
and other symptoms included dizziness, headache, and paresthe-
sias. One patient discontinued LEV after developing panic attacks.
This research group conducted a second chart review with a sam-
ple of patients with metastatic brain tumors (33) and reviewed
the charts of 13 patients receiving LEV as monotherapy (46%) or
add-on therapy (54%). At 4 weeks follow-up, 46 percent of the
sample had adverse side effects including somnolence, headache,
blurry vision, and nausea and vomiting.
Rosati et al. (34) conducted a prospective study with 176 newly
diagnosed glioma patients. All patients diagnosed with epilepsy
(47% of the sample) were initially treated with LEV. Two patients
discontinued LEV during the study because of intolerable diar-
rhea and visual hallucinations with psychotic thoughts. de Groot
et al. (20) also looked at patients with glioma and one patient
from their sample of 35 discontinued LEV before follow-up data
were gathered due to side effects including leukopenia. Wagner
et al. (35) conducted a feasibility study looking at LEV in pri-
mary brain tumor patients. Their sample included 26 patients.
Thirty-five percent of the sample reported side effects which most
frequently consisted of fatigue, somnolence, and dizziness. One
patient discontinued LEV after developing psychosis. Maschio et
al. (21) also conducted a prospective study exploring the effective-
ness of three newer AEDs (LEV, oxcarbazepine, topiramate) in a
group of 30 patients with brain metastases. Six of the patients were
taking LEV. Only three patients from the sample developed mild
side effects. Two of the three were taking LEV and developed mild
and reversible restlessness and rash.
Two comparative studies were found that compared LEV to
phenytoin (22, 24). One study compared a group of 105 patients
receiving LEV monotherapy with 210 patients receiving pheny-
toin monotherapy and found the patients prescribed LEV had
fewer side effects. One patient discontinued LEV due to develop-
ing visual hallucinations, and 38 patients discontinued phenytoin
due to various side effects (22). Another study that compared
LEV to phenytoin included 29 patients post-craniotomy who were
randomized into either a phenytoin group or a LEV group. At
3 months follow-up, patients using LEV were reporting fewer side
effects in many areas, though they endorsed more difficulty sleep-
ing (33% of LEV subjects) and emotional instability (13%) as
compared to the patients in the phenytoin group [(24), p. 353].
One patient reported increased hostility toward others after begin-
ning LEV, though this was not severe enough to discontinue the
medication. Zachenhofer et al. (36) retrospectively studied 78
brain tumor patients receiving LEV following surgery. Side effects
were reported in 6.4% of the sample, with three patients report-
ing progressive somnolence and two patients developing reactive
psychosis.
Two studies were reviewed that included screens of cognitive
functioning in their assessment of side effects. Usery et al. (37)
Frontiers in Neurology | Epilepsy July 2013 | Volume 4 | Article 99 | 2
Bernett et al. Keppra and brain tumors
completed a prospective open-label study looking at the safety and
tolerability of intravenous and oral LEV following neurosurgery.
The study was hindered by a small sample and only included 17
patients. The patients were followed for 1 month after discharge
and six adverse events were reported including three episodes of
somnolence, and one episode each of nausea/vomiting, headache,
and insomnia. The researchers also used the Telephone Inter-
view for Cognitive Status (TICS) (38) to evaluate weekly for any
cognitive changes secondary to LEV. Two patients were deemed
cognitively impaired due to their scores on this measure. It should
be noted that the TICS is normed for individuals aged 60–98 years,
and the current sample’s mean age was 56 with a range from 27 to
77. This would suggest that some of the participants were younger
than the normative sample of the TICS, and thus their scores may
be inaccurate.
Dinapoli et al. (39) conducted a case series to evaluate LEV
as a monotherapy for brain tumor related epilepsy in a sample
of 18 patients that they followed for 6 months. The Mini Men-
tal Status Examination (MMSE) (40) was used as a measure of
global cognitive function and the Karnofsky Performance Scale
(KPS) (41) and the Bartel Index (BI) (42) were used to evalu-
ate overall functioning. Sixty one percent of the sample had side
effects at the beginning of the trial including rash, somnolence,
periarthritis, weight loss, and liver toxicity. At 6 months 22.2%
had mild side effects including somnolence and restlessness. At
6 months scores on all three measures were significantly worse
than at baseline, though the MMSE mean score was still in the nor-
mal range (KPS 85.83, BI 87.78, and MMSE 26.78). This research
group has also published two other studies, one of which fol-
lowed 29 patients for 12 months (43). In terms of side effects, three
patients reported restlessness, and one discontinued LEV due to
the severity of the restlessness. Two patients reported somnolence.
An earlier study by these researchers (44) looked at 19 patients
with supratentorial gliomas and found the majority of patients
had improved seizure frequency and no adverse side effects were
reported.
CONCLUSION
The existing research regarding LEV and brain tumor related
epilepsy appears to provide support for the drug’s efficacy in
reducing seizures. However, its neurobehavioral profile in this
population remains somewhat unclear and the existing research
has primarily focused on the drug’s anti-epileptic properties and
tolerability. Given that LEV has a well-established neurobehav-
ioral profile in the general epilepsy population, namely associ-
ated behavior change and increased aggression, it is important
to examine whether a similar profile appears in patients with
co-morbid neurological conditions (e.g., tumors). Several stud-
ies were reviewed that reported on side effects seen in brain
tumor samples and the results varied widely, ranging from no
side effects (44) to 58.5% of a sample reporting side effects (32).
In terms of neurobehavioral changes, irritability (6), emotional
instability (24), and restlessness (39) were seen in some patients.
Interestingly, only once study mentioned a participant developing
increased hostility toward others, though it was not severe enough
to discontinue LEV (24). Multiple studies had patients who dis-
continued LEV due to significant psychiatric symptoms including
panic attacks and psychotic symptoms (23, 32, 34–36).
The existing research has a number of limitations that make
it difficult to draw conclusions across studies. Many of the stud-
ies were retrospective chart reviews and sample sizes tended to
be quite small. Only one study was found that was prospective
and randomized (37) and the study was closed early after only
obtaining 17 participants.
Side effect data was typically gathered by self-report and
focused primarily on health status (e.g., the Adverse Events Pro-
file). Only two studies were found that included a brief cognitive
screening instrument (37, 39) and no research studies included
formal neuropsychological testing. In general, the focus of the
existing research tended to be on seizure reduction while other
areas were not fully explored.
Additional research is necessary to identify the neurobehav-
ioral profile of LEV in brain tumor related epilepsy, as general
conclusions cannot be drawn from the existing research. LEV does
appear to have some support for its efficacy in terms of reducing
seizure frequency and may have fewer side effects in compari-
son to other AEDs (23). However, the side effects reported across
different studies varied widely, and it is unclear if there are par-
ticular patient characteristics (e.g., tumor location) that might
interact with the drug of choice. Additional research that more
fully explores the neurobehavioral effects of LEV in patients with
brain tumors would be useful in order to improve patient care
and allow providers to make a more fully informed decision when
choosing a treatment option.
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